Jade Biosciences (JBIO) Net Equity Issued and Repurchased (2021 - 2024)

Jade Biosciences (JBIO) posted Net Equity Issued and Repurchased of $307000.0 for Q4 2024, up 222.8% on a QoQ basis from -$250000.0 in Q4 2021.

Jade Biosciences (JBIO) Net Equity Issued and Repurchased (2021 - 2024) Analysis & Trends

Jade Biosciences' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $307000.0 for Q4 2024.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $307000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $307000.0 (down 99.52% YoY) and the FY2024 annual result came in at $23.9 million, down 46.66% from the prior year.
Net Equity Issued and Repurchased was $307000.0 for Q4 2024 at Jade Biosciences, up from -$250000.0 in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $63.7 million in Q3 2021 and bottomed at -$250000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	141.90 Mn
10	Jade Biosciences	1.18 Bn	866.20 Mn	-	-

Download Data